Clinical trials: Operable Breast Neoplasms
Neoadjuvant Chemotherapy
Muscle Parameters and Pathological Response in Breast Cancer Patients
The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
- Trial name
- NCT06151379
- Testing
- Neoadjuvant therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 69 people
- Sponsor
- Acıbadem Atunizade Hospital
Breast Cancer
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00769470
- Testing
- trastuzumab, carboplatin, docetaxel
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- Translational Oncology Research International
Breast Cancer
Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
The main purpose of this study is to find out what effects taking the drug bevacizumab together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by doxorubicin alone before surgery will on breast cancer.
- Trial name
- NCT00203502
- Testing
- Bevacizumab, Cyclophosphamide, Docetaxel
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Breast Cancer
Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer
The purpose of this study is to determine pathological response to a maximum of 18 weeks of neoadjuvant therapy using a combination of letrozole and Bevacizumab in post-menopausal women with pathologically confirmed invasive…
- Trial name
- NCT00161291
- Testing
- Letrozole in combination with Bevacizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer
Sentinel Lymph Node Biopsy to Assess Axillary Lymph Nodes in Women With Stage I or Stage II Breast Cancer
RATIONALE: Diagnostic procedures such as sentinel lymph node biopsy may improve the ability to detect breast cancer and determine the extent of disease.
- Trial name
- NCT00005821
- Testing
- patent blue V dye, conventional surgery, lymphangiography
- Where
- 4 sites in United Kingdom
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer
Some studies have demonstrated the efficacy of Abraxane in treating breast cancer in both adjuvant and metastatic settings. Few data is available on Abraxane in neoadjuvant treatment for breast cancer.
- Trial name
- NCT03647514
- Testing
- Abraxane, Xeloda
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Cancer, Breast
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients
Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients with Operable or Locally Advanced /Inflammatory HER2-positive Breast Cancer…
- Trial name
- IMMUN-HER (NCT03144947)
- Testing
- Trastuzumab IV, Trastuzumab SC, Pertuzumab
- Where
- 21 sites in Italy
- Volunteers
- 65 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Breast Cancer
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
The primary objective is to determine the feasibility of combining pembrolizumab with a single fraction radiation boost in patients with early/ operable breast cancer.
- Trial name
- BreastVAX (NCT04454528)
- Testing
- Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
NSABP Biospecimen Discovery Project
This study is a biospecimen discovery project that will serve as a pilot for a comprehensive 'omics approach using fresh core biopsy tissue and blood samples for DNA and protein analysis, as well as paired tumor-normal exome DNA…
- Trial name
- NCT01850628
- Testing
- Paclitaxel, trastuzumab, pertuzumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
This is a prospective, non-randomized, open-label, multicenter, single-arm exploratory pharmacogenomic study of single agent eribulin as neoadjuvant therapy in patients with operable Stage III HER2 non-overexpressing breast…
- Trial name
- NeoEribulin (NCT01669252)
- Testing
- Eribulin
- Where
- 30 sites in France, Germany and 2 more
- Volunteers
- 163 people
- Sponsor
- SOLTI Breast Cancer Research Group
Pathological Response Rate
Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".
- Trial name
- TVA (NCT00933517)
- Testing
- vectibix, fluorouracile, Epirubicine
- Where
- 12 sites in France
- Volunteers
- 62 people
- Sponsor
- Centre Jean Perrin
Breast Cancer, Surgery
Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer
Breast carcinoma requires frequently an adjuvant therapy after surgical excision: in this way, one of the major criteria indicating the need of adjuvant chemotherapy is the diagnosis of a metastatic lymph-node invasion, mainly in…
- Trial name
- SAGE (NCT02056886)
- Testing
- SLN detection +/- complementary axillary lymphadenectomy
- Where
- 17 sites in France
- Volunteers
- 858 people
- Sponsor
- Institut Cancerologie de l'Ouest
Invasive Ductal and Invasive Lobular Breast Carcinoma, Stage 0 Breast Carcinoma
Single Fraction Intraoperative Radiotherapy
This clinical trial is being conducted to find out the effects (good and bad) of giving the full radiation treatment for breast cancer as a single dose of radiation during surgery for breast cancer.
- Conditions
- Invasive Ductal and Invasive Lobular Breast Carcinoma, Stage 0 Breast Carcinoma, Stage I Breast Carcinoma, Stage II Breast Carcinoma
- Trial name
- NCT01688388
- Testing
- Intraoperative Radiotherapy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- St. Joseph Hospital of Orange
Breast Cancer
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00373191
- Testing
- chemotherapy, endocrine therapy, DNA methylation analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Neoplasms
German Preoperative Adriamycin Docetaxel Study
The primary objective of this trial is to determine the rate of pathologically complete remissions following a preoperative dose-intensified therapy with doxorubicin and docetaxel with or without tamoxifen in patients with…
- Trial name
- NCT00543829
- Testing
- doxorubicin, docetaxel, tamoxifen, doxorubicin, docetaxel
- Volunteers
- 250 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer
It has been found that many breast cancers are hormone dependent and that hormonal therapy by estrogen suppression such as ovarian ablation, tamoxifen and aromatase inhibitor has proven beneficial in both adjuvant and neoadjuvant…
- Trial name
- NCT00488722
- Testing
- Zoladex
- Where
- China
- Sponsor
- Tianjin Medical University
Breast Cancer
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
The efficacy of adjuvant chemotherapy is limited in patients with a high risk of recurrence. Also, for axillary positive node patients, optimum chemotherapy regimens are still under discussion.
- Trial name
- NCT00129922
- Testing
- paclitaxel, Fluorouracil, Epirubicin
- Where
- 64 sites in Spain
- Volunteers
- 1,289 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
Primary objective of the study in patients without a sufficient sonographic response (i.e. iNC) to 2 cycles of TAC as preoperative treatment of operable (T>/= 2cm, N0-2,M0) primary breast cancer: To determine the response rate…
- Trial name
- GeparTrio (NCT00544765)
- Testing
- TAC, NX
- Volunteers
- 2,014 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive…
- Trial name
- APHINITY (NCT01358877)
- Testing
- 5-Fluorouracil, Carboplatin, Cyclophosphamide
- Where
- 546 sites in United States, Argentina and 40 more
- Volunteers
- 4,804 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
This study is being done to assess the feasibility of pembrolizumab (study drug) combined with standard radiation to the tumor (tumor boost) before patients undergo standard treatment that can consist of one or more of the…
- Trial name
- NCT03366844
- Testing
- Pembrolizumab, RT Boost
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Stephen Shiao